Modeling Hepatic Fibrosis and Screening Anti-Fibrotic Compounds Based on Multi-Lineage Hepatic Organoids
This study establishes a physiologically relevant 3D multi-lineage human liver organoid platform for fibrosis modeling and drug screening, identifying the novel aspirin derivative AS191 as a potent therapeutic agent that mitigates hepatic fibrosis by inhibiting the non-canonical TGF-β/PI3K/AKT signaling pathway.
Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). This is an AI-generated explanation of a preprint that has not been peer-reviewed. It is not medical advice. Do not make health decisions based on this content. Read full disclaimer
The liver is the body's tireless chemical plant, filtering blood, storing energy, and neutralizing toxins to keep the internal environment stable. When this organ suffers repeated injury from viruses, alcohol, or metabolic issues, it attempts to heal itself by laying down scar tissue. This process, known as fibrosis, is a natural response to damage, but when it goes unchecked, the scar tissue accumulates like a thickening layer of concrete. Over time, this hardening disrupts the flow of blood and nutrients, eventually causing the organ to fail. For decades, scientists have struggled to find drugs that can reverse this scarring because the standard ways of testing medicines in the lab often fail to capture the complex, three-dimensional reality of human liver tissue. Most lab models are too simple, missing the crucial interactions between different types of cells that drive the disease forward.
To solve this problem, a team of researchers at the Tianjin Institute of Pharmaceutical Research and Shenyang Pharmaceutical University built a new kind of test tube model that mimics the human liver much more closely than previous attempts. They created tiny, three-dimensional spheres of living tissue, which they call organoids, by mixing three specific types of human cells together: liver cells, blood vessel cells, and the cells responsible for creating scar tissue. By growing these cells together in a gel, they formed a miniature, functional liver that behaves like the real thing. Using this advanced model, the team successfully induced a state of fibrosis by exposing the organoids to a specific protein known to trigger scarring. This allowed them to watch the disease develop in a controlled environment and test hundreds of potential drugs to see which ones could stop the process.
From a large library of candidate compounds, the researchers identified a promising new substance called AS191, a derivative of aspirin. When they treated the fibrotic organoids with AS191, the drug effectively stopped the cells from producing excessive scar tissue. To understand exactly how this worked, the team looked deep inside the cells to see which biological signals were being turned on or off. They discovered that AS191 did not work through the most common pathway scientists usually study for liver scarring. Instead, it blocked a different, less familiar signaling route that involves a chain of proteins known as PI3K and AKT. By shutting down this specific chain of commands, the drug prevented the scar-making cells from activating and laying down new collagen, the main component of scar tissue.
The team did not stop at the petri dish. To confirm that their findings held true in a living system, they tested AS191 on mice that had been given a chemical to induce liver fibrosis. The results in the animals mirrored what they saw in the lab. The mice treated with AS191 showed significantly less scar tissue in their livers, and their liver function improved, with lower levels of enzymes that indicate organ damage. The drug successfully reduced the activation of the same signaling pathway they had identified in the human cells, confirming that the mechanism was consistent across different biological systems. This dual validation, using both sophisticated human cell models and animal studies, suggests that AS191 has strong potential as a treatment for liver fibrosis.
While the results are encouraging, the researchers are careful to note that this is still an early stage of discovery. The human liver is a complex organ with many different cell types, including immune cells that were not included in their current model. The study also used a single type of animal model, which may not perfectly represent the variety of causes that lead to liver disease in humans. Furthermore, the long-term safety and effectiveness of the drug in people have not yet been tested. Despite these limitations, the study provides a significant step forward in two ways. First, it demonstrates that these multi-cell organoids are a reliable and powerful tool for studying liver disease and screening new drugs, offering a more accurate alternative to traditional methods. Second, it identifies a specific, new target for future therapies, offering hope that one day, doctors may have a way to treat and potentially reverse the scarring that leads to liver failure.
Drowning in papers in your field?
Get daily digests of the most novel papers matching your research keywords — with technical summaries, in your language.